ArticleThe Journal of international medical research2017
Prevalence and risk factors of multi-drug resistant tuberculosis in Dalian, China.
Article in The Journal of international medical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Global prevalence of drug-resistant tuberculosis: a systematic review and meta-analysis.Infectious diseases of poverty · 2023Pooled it
- Differential yield of universal versus selective drug susceptibility testing of patients with tuberculosis in high-burden countries: a systematic review and meta-analysis.BMJ global health · 2020Pooled it
- Patterns of Drug Resistance and Treatment Outcomes in Drug-Resistant Tuberculosis Patients in Fuyang City: A Three-Year Retrospective Study.Infection and drug resistance · 2026Article
- Magnitude, predictors, and trends of multidrug-resistant tuberculosis among tuberculosis patients at Debre Markos, Northwest, Ethiopia: a five-year retrospective study.JAC-antimicrobial resistance · 2025Article
- Analysis on epidemiological and drug resistance characteristics of lymph node tuberculosis from Hunan province, China.Frontiers in public health · 2024Article
- First and Second-Line Anti-Tuberculosis Drug-Resistance Patterns in Pulmonary Tuberculosis Patients in Zambia.Antibiotics (Basel, Switzerland) · 2023Article
- Epidemiological characteristics and risk factors of multidrug-resistant tuberculosis in Luoyang, China.Frontiers in public health · 2023Article
- Characteristics of TB/HIV Co-Infection and Patterns of Multidrug-Resistance Tuberculosis in the Northwest Amhara, Ethiopia.Infection and drug resistance · 2023Article
- A retrospective study on risk factors and disease burden for hospital-acquired pneumonia caused by multi-drug-resistant bacteria in patients with intracranial cerebral hemorrhage.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Article
- Drug resistance characteristics ofEpidemiology and infection · 2022Article
- Prevalence of Multidrug-Resistant TB Among Smear-Positive Pulmonary TB Patients in Banadir, Somalia: A Multicenter Study.Infection and drug resistance · 2022Article
- Differentiating between drug-sensitive and drug-resistant tuberculosis with machine learning for clinical and radiological features.Quantitative imaging in medicine and surgery · 2022Article
- Prevalence of Drug-Resistant Tuberculosis in Sudan: A Systematic Review and Meta-Analysis.Antibiotics (Basel, Switzerland) · 2021Article
- Factors Associated with Multi-Drug Resistant Tuberculosis among TB Patients in Selected Treatment Centers of Amhara Region: A Case-Control Study.Ethiopian journal of health sciences · 2021Article
- Prevalence of Multidrug-Resistant Tuberculosis in Dalian, China: A Retrospective Study.Infection and drug resistance · 2021Article
- Drug-Resistant Mycobacterium tuberculosis Isolates from New and Previously Treated TB Patients in China, 2017-2019.Revista da Sociedade Brasileira de Medicina Tropical · 2021Article
- Article
- Characteristics of pulmonary multidrug-resistant tuberculosis patients in Tigray Region, Ethiopia: A cross-sectional study.PloS one · 2020Article
- DeterminingInfection and drug resistance · 2020Article
- Response to "Comment on Wang et al.: One-stage posterior focus debridement, interbody graft using titanium mesh cages, posterior instrumentation and fusion in the surgical treatment of lumbo-sacral spinal tuberculosis in the aged".International orthopaedics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives To investigate the prevalence and risk factors associated with multi-drug resistant tuberculosis (MDR-TB) in Dalian, China. Methods This was a retrospective review of data from patients attending a TB clinic in Dalian, China between 2012 and 2015. Demographic and drug susceptibility data were retrieved from TB treatment cards. Univariate logistic analysis was used to assess the association between risk factors and MDR-TB. Results Among the 3552 patients who were smear positive for Mycobacterium tuberculosis (MTB), 2918 (82.2%) had positive MTB cultures and 1106 (31.1%) had isolates that showed resistance to at least one drug. The overall prevalence of MDR-TB was 10.1% (359/3552; 131/2261 [5.8%] newly diagnosed and 228/1291 [17.7%] previously treated patients). Importantly, 75 extensively drug-resistant TB isolates were detected from 25 newly treated and 50 previously treated patients. In total, 215 (6.1%) patients were infected with a poly-resistant strain of MTB. Previously treated patients and older patients were more likely to develop MDR-TB. Conclusions The study showed a high prevalence of MDR-TB among the study population. History of previous TB treatment and older age were associated with MDR-TB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.